Annual Operating Expenses
$20.09 M
+$1.96 M+10.82%
31 December 2023
Summary:
Inhibikase Therapeutics annual total operating expenses is currently $20.09 million, with the most recent change of +$1.96 million (+10.82%) on 31 December 2023. During the last 3 years, it has risen by +$17.27 million (+612.78%). IKT annual operating expenses is now at all-time high.IKT Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Expenses
$5.83 M
+$777.00 K+15.38%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly total operating expenses is currently $5.83 million, with the most recent change of +$777.00 thousand (+15.38%) on 30 September 2024. Over the past year, it has increased by +$1.06 million (+22.20%). IKT quarterly operating expenses is now -6.04% below its all-time high of $6.20 million, reached on 30 June 2023.IKT Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +10.8% | +22.2% |
| 3 y3 years | +612.8% | +30.3% |
| 5 y5 years | +846.7% | +383.8% |
IKT Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +612.8% | -6.0% | +34.4% |
| 5 y | 5 years | at high | +846.7% | -6.0% | +1308.0% |
| alltime | all time | at high | +846.7% | -6.0% | +1308.0% |
Inhibikase Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $5.83 M(+15.4%) |
| June 2024 | - | $5.05 M(+5.6%) |
| Mar 2024 | - | $4.78 M(+8.6%) |
| Dec 2023 | $20.09 M(+10.8%) | $4.40 M(-7.7%) |
| Sept 2023 | - | $4.77 M(-23.1%) |
| June 2023 | - | $6.20 M(+31.5%) |
| Mar 2023 | - | $4.71 M(+8.8%) |
| Dec 2022 | $18.13 M(+22.8%) | $4.33 M(-3.9%) |
| Sept 2022 | - | $4.51 M(-2.7%) |
| June 2022 | - | $4.64 M(-0.0%) |
| Mar 2022 | - | $4.64 M(-8.0%) |
| Dec 2021 | $14.77 M | $5.04 M(+12.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | $4.47 M(+70.1%) |
| June 2021 | - | $2.63 M(+0.1%) |
| Mar 2021 | - | $2.63 M(+118.6%) |
| Dec 2020 | $2.82 M(-50.5%) | $1.20 M(+80.9%) |
| Sept 2020 | - | $663.70 K(+60.4%) |
| June 2020 | - | $413.90 K(-23.4%) |
| Mar 2020 | - | $540.00 K(+27.9%) |
| Dec 2019 | $5.70 M(+168.5%) | $422.30 K(-64.9%) |
| Sept 2019 | - | $1.20 M(-48.5%) |
| June 2019 | - | $2.34 M(+35.0%) |
| Mar 2019 | - | $1.73 M |
| Dec 2018 | $2.12 M | - |
FAQ
- What is Inhibikase Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual operating expenses year-on-year change?
- What is Inhibikase Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly operating expenses year-on-year change?
What is Inhibikase Therapeutics annual total operating expenses?
The current annual operating expenses of IKT is $20.09 M
What is the all time high annual operating expenses for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual total operating expenses is $20.09 M
What is Inhibikase Therapeutics annual operating expenses year-on-year change?
Over the past year, IKT annual total operating expenses has changed by +$1.96 M (+10.82%)
What is Inhibikase Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of IKT is $5.83 M
What is the all time high quarterly operating expenses for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly total operating expenses is $6.20 M
What is Inhibikase Therapeutics quarterly operating expenses year-on-year change?
Over the past year, IKT quarterly total operating expenses has changed by +$1.06 M (+22.20%)